Navigation Links
Arstasis Launches New AXERA™ Access Device in the U.S.
Date:5/16/2011

REDWOOD CITY, Calif., May 16, 2011 /PRNewswire/ -- Arstasis is pleased to announce the U.S. launch of its latest commercial product - the AXERA™ Access Device.  The AXERA Device enhances insertability into the femoral artery and overall procedural usage while continuing to deliver the clinical benefits of the implant-free Arstaotomy Procedure.

Since 1959, physicians have been using the Modified Seldinger Technique for femoral artery access.  At the end of every such case, patients are left with a substantial hole in the femoral artery which can command significant effort and cath lab resources to close.  The AXERA™ Access Device is a breakthrough femoral artery access tool that quickly creates a longer and shallower angle arteriotomy, the Arstaotomy, resulting in significant tissue-upon-tissue overlap through the artery. Upon sheath removal at the end of the procedure, arterial pressure is decreased across this longer Arstaotomy channel intended to provide an excellent environment for clot formation and rapid femoral artery hemostasis.

The AXERA Device's Arstaotomy Procedure requires only minimal manual compression to provide secure closure with no foreign body implants - eliminating the risk of infections and thromboembolic events related to a vascular implant. The Arstaotomy Procedure promotes rapid hemostasis resulting in excellent patient comfort with decreased bed rest and quicker ambulation.

"The AXERA Access Device delivers a truly unique way to gain access into the femoral artery for diagnostic and cath-possible procedures," commented Dale Wortham, MD from the University of Tennessee Medical Center, Knoxville.  "Unlike vascular closure implants, the AXERA Device delivers rapid arterial hemostasis but does not deposit any foreign material into the patient.  Our results have been excellent with patients generally sitting up in 15 minutes and ambulating in 1 hour.  It really has improved our cath lab throughput and patient satisfaction."

Physicians have also been noting that the new AXERA Device allows them to perform Arstaotomy procedures in almost all patients, instead of having to potentially exclude patients with complex anatomy.  "In my opinion, all patients are candidates for the AXERA Access Device.  The new AXERA Device is sturdier and allows me to more easily gain femoral artery access, even in the more complicated patient subsets of the obese and those with heavily diseased vessels," said Dr. Greg Sampognaro, a practicing interventional cardiologist at the P&S Surgical Hospital in Monroe, Louisiana.

Patient enrollment continues in the RECITAL study, a multi-center, prospective registry that is overseen by a medical monitor and anticipated to enroll up to 500 patients in at least seven U.S. hospitals.

ABOUT ARSTASIS, INC.

Arstasis, Inc., headquartered in Redwood City, California, is a medical device manufacturer dedicated to bringing innovative arterial access devices to cardiologists, interventional radiologists, their staffs, and patients.  Detailed information about the AXERA Access Device and the Arstaotomy procedure is available at www.arstasis.com.

INVESTOR/MEDIA CONTACT
Alexander Arrow, CFO
(650) 508-1549
investorrelations@arstasis.com


'/>"/>
SOURCE Arstasis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants
2. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
3. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
4. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
5. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
8. Premier Micronutrient Launches Supplement for Hearing Health
9. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
10. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
11. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
Breaking Medicine News(10 mins):